Skip to main content

Pfizer Falls Short of Profit Targets

Increased generic-drug competition weighs on first-quarter earnings.


(PFE) - Get Pfizer Inc. Report

missed Wall Street estimates Thursday amid generic-drug pressures and declining sales of its multibillion-dollar drug Lipitor, but the Big Pharma reaffirmed its 2008 guidance.

Shares fell 74 cents, or 3.5% to $20.36 in morning trading.

The New York-based company said Thursday that it earned $2.78 billion, or 41 cents a share, in the recent quarter, down from $3.3 billion, or 48 cents a share, in the year ago quarter. On an adjusted basis, net income fell to $4 billion, or 61 cents a share, from $4.8 billion, or 68 cents a share, in the 2007 period. Revenue declined to $11.8 billion from $12.4 billion in the quarter.

Scroll to Continue

TheStreet Recommends

Results were short of the consensus estimate offered by analysts surveyed by Thomson Financial. They were looking for earnings of 66 cents a share on roughly $12 billion in revenue.

Pfizer said declines in revenue were mainly attributable to the loss of U.S. exclusivity for Norvasc and Zyrtec. Those two drugs alone accounted for a combined $900 million decrease in revenue during the first quarter.

Pharmaceutical revenue altogether decreased 6%, including a 7% decrease in worldwide sales of cholesterol-lowering drug Lipitor to $3.1 billion. This included an 18% decrease of sales of the drug in the U.S.

Of Pfizer's smaller drugs, anti-inflammatory Celebrex saw revenue edge up just 2% year over year to $611 million. But Lyrica revenues increased 47% to $582 million, with strong growth in fibromyalgia.

Newer product, cancer treatment Sutent saw sales of $190 million, and smoking-cessation drug Chantix resulted in $277 million in first-quarter revenue.

Looking ahead, the company reaffirmed expectations for adjusted earnings of between $2.35 and $2.45 a share on revenue of between $47 billion and $49 billion. The guidance is in line with expectations of analysts surveyed by Thomson Financial who have pegged $2.39 a share on revenue of $48.3 billion.